COmparison of White Light and Linked COlor Imaging for Detection of RIght COlon Polyps

Overview

Comparison of the number of adenomas missed by the first exploration of the right colon by LCI (linked color imaging) or by white light during a colonoscopy, according to the order of randomization.

Full Title of Study: “COmparison of White Light and Linked COlor Imaging for Detection of RIght COlon Polyps: A Multi Center Prospective Randomized Tandem Colonoscopy Study”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Diagnostic
    • Masking: None (Open Label)
  • Study Primary Completion Date: January 1, 2022

Detailed Description

All patients consecutively admitted for routine colonoscopy will be included in this prospective randomized crossover study. After randomization, a first exploration of the right colon will be performed in linked color imaging (LCI) or white light imaging (WLI) depending of the randomization. Every polyp will be resected as soon it will be detected. After this first examination, colon will be explored a second time with a light system different from the one used for the first exploration. If a polyp will be detected during the second exploration, it will be counted as a polyp missed by the first exploration method. A- Inclusion criteria: 1. Patient consecutively admitted to one of the endoscopy units for routine colonoscopy (screening, positive FIT, personal or family history of polyp or cancer, symptoms) 2. Patient whose age is greater than or equal to 18 years and less than 90 years 3. Score: ASA 1, ASA 2, ASA 3 4. No participation in another clinical study 5. Signed informed consent Exclusion criteria: History of recto-colic resection Inadequate preparation (none under Boston score <2) Patient referred for resection of a polyp in place, known IBD (inflammatory bowel disease) or known polyposis B- Exclusion criteria: 1. History of recto-colonic resection 2. Inadequate preparation (none under Boston score <2) 3. Patient referred for resection of a known polyp 4. Inflammatory Bowel Disease 5. family polyposis 6. Score: ASA 4, ASA 5 7. Pregnant woman 8. Patient with coagulation abnormalities preventing polyp resection: TP <50%, Platelets <50000 / mm3, effective anticoagulation in progress, clopidogrel in progress 9. Patient unable to personally consent 10. No signed informed consent Purposes of the study: Compare, when exploring the number of adenomas missed by the first exploration of the right colon by LCI or by white light, according to the order of randomization. Evaluation criteria : Main criterion: – Missed right colon adenomas by first exploration in LCI-WLI and WLI-LCI groups Secondary criteria – Rate of polyps missed by the first exploration – Serrated polyp rate missed by the first exploration – Advanced adenoma rate missed by the first exploration – Comparison of ADR, SPDR, given by the first exploration technique decided by randomization Number of patients: The expected rate of "missed adenomas" of the colon is about 20%, based on published data. Considering as relevant an 8% reduction in this rate of "missed adenomas" of the right colon by the LCI, the expected rate for LCI is therefore 12%. With a risk of the first species of 5% (bilateral test), a power of 80%, 329 patients per group should be included in the study. Taking into account the rate lost to follow-up of 5%, we expect a total of 700 patients. Duration of the study: 1-2 years

Interventions

  • Procedure: exploration in white light (WLI)
    • Exploration of the right colon done in white light (WLI)
  • Procedure: Exploration in LCI
    • Exploration of the right colon in linked color imaging (LCI)

Arms, Groups and Cohorts

  • Active Comparator: WLI-LCI group
    • a first exploration of the right colon will be done in white light (WLI) then a second exploration will be done in LCI
  • Active Comparator: LCI-WLI group
    • a first exploration of the right colon will be done in LCI and a second exploration will be done in white light (WLI)

Clinical Trial Outcome Measures

Primary Measures

  • the number of missed adenomas during the first exploration of the right colon
    • Time Frame: 1 day
    • Number of polyps diagnosed on the second exploration and not removed (because not diagnosed) during the first exploration

Secondary Measures

  • The factors influencing these missed polyp rates
    • Time Frame: 1 day
    • Time of exploration (in seconds)
  • The factors influencing these missed polyp rates
    • Time Frame: 1 day
    • Boston scale (0 to 9)
  • The characteristics of the missed polyps
    • Time Frame: 1 day
    • Size in millimeters
  • The characteristics of the missed polyps
    • Time Frame: 1 day
    • type : Adenoma polyp / Advanced neoplasia polyp / Serrated polyp / Hyperplastic polyp
  • Adenoma Detection Rate (ADR)
    • Time Frame: 1 day
    • given by the first exploration technique decided by randomization: percentage of colonoscopy with one or more adenoma of the right colon
  • Advanced Neoplasia Detection Rate (ANDR)
    • Time Frame: 1 day
    • given by the first exploration technique decided by randomization: percentage of colonoscopy with one or more advanced neoplasia of the right colon
  • Serrated Polyp Detection Rate (SPDR)
    • Time Frame: 1 day
    • given by the first exploration technique decided by randomization: percentage of colonoscopy with one or more serrated polyp of the right colon

Participating in This Clinical Trial

Inclusion Criteria

  • Patient consecutively admitted for routine colonoscopy Exclusion Criteria:

  • History of recto-colic resection – Inadequate preparation (none under Boston score <2) – Patient referred for resection of a known polyp – known Inflammatory Bowel Disease (IBD) or known polyposis

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 90 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Société Française d’Endoscopie Digestive
  • Provider of Information About this Clinical Study
    • Principal Investigator: KARSENTI, Principal investigator – Société Française d’Endoscopie Digestive
  • Overall Official(s)
    • David KARSENTI, MD, Principal Investigator, Société Française d’Endoscopie Digestive
  • Overall Contact(s)
    • David KARSENTI, MD, +33 1 45 48 65 65, karsenti@club-internet.fr

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.